http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017532327-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate | 2015-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017532327-A |
| titleOfInvention | Crystal form of hydrogen sulfate of JAK kinase inhibitor and process for producing the same |
| abstract | The present invention relates to a crystal form of a hydrogen sulfate salt of a JAK kinase inhibitor and a method for producing the same. Specifically, the present invention relates to (3aR, 5s, 6aS) -N- (3-methoxyl-1,2,4-thiadiazol-5-yl) -5- (methyl (7H-pyrrolo [2,3-d ] Pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrole-2 (1H) -formamide hydrogensulfate type II crystals and process for the production thereof. The preparation process comprises dissolving any crystalline or amorphous solid of the compound of formula (I) in a single or mixed organic solvent to obtain type II crystals of the compound of formula (I). The type II crystals of the compound of formula (I) obtained in the present invention have good crystal stability and chemical stability, and the recrystallization solvent used has low toxicity and persistence, and is better applied to clinical treatment it can. [Selection figure] None |
| priorityDate | 2014-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.